Paradoxical effects of atorvastatin on renal tubular cells an experimental investigation

Iranian Journal of Kidney Diseases

Volumn 9, Issue 3, 2015, Pages 215-220

  Hasanpour, Zahra ^a   Nasri, Hamid ^a   Rafieian Kopaei, Mahmoud ^b   Ahmadi, Ali ^b   Baradaran, Azar ^a   Nasri, Parto ^a   Nematbakhsh, Mehdi ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute kidney injury; Animal model; Antioxidant activity; Atorvastatin; Gentamicin

Indexed keywords

ATORVASTATIN; GENTAMICIN; CREATININE; HYPOCHOLESTEROLEMIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL STRUCTURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; GENTAMICIN INDUCED KIDNEY INJURY; HISTOPATHOLOGY; KIDNEY INJURY; KIDNEY TUBULE CELL; MALE; MICROSCOPY; NEPHROTOXICITY; NONHUMAN; PARADOXICAL DRUG REACTION; RAT; UREA NITROGEN BLOOD LEVEL; ANIMAL; BLOOD; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; INJURIES; KIDNEY; KIDNEY TUBULE; PATHOLOGY; TIME FACTOR; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; BLOOD UREA NITROGEN; CREATININE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENTAMICINS; KIDNEY; KIDNEY TUBULES; MALE; RATS; RATS, WISTAR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928995174     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Plosker GL, Lyseng-Williamson KA. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events. Pharmacoeconomics. 2007;25:1031-53.
2. Perk J, Graham I, De BG. Prevention of cardiovascular disease: new guidelines, new tools, but challenges remain. Heart. 2014;100:675-7.
3. Cai J, Yu X, Zhang B, et al. Atorvastatin improves survival of implanted stem cells in a rat model of renal ischemiareperfusion injury. Am J Nephrol. 2014;39:466-75.
4. Sanadgol H, Abdani S, Tabatabaiee P, Mohammadi M. Protective effect of high dose short term statin therapy with normal saline in prevention of contrast-induced nephropathy among iodixanol-receiving patients. J Renal Inj Prev. 2012;1:43-5.
5. Kaya A, Kurt M, Tanboga IH, et al. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial). Acta Cardiol. 2013;68:489-94.
6. Spasovski D. Renal markers for assessment of renal tubular and glomerular dysfunction. J Nephropharmacol. 2013; 2:23-25.
7. Pickering JW, Endre ZH. The definition and detection of acute kidney injury. J Renal Inj Prev. 2014;3:21-5.
8. Tamadon MR, Ardalan MR, Nasri H. World Kidney Day 2013; acute renal injury; a global health warning. J Parathyr Dis. 2013;1:27-8.
9. Mose FH, Larsen T, Jensen JM, Hansen AB, Bech JN, Pedersen EB. Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease. Br J Clin Pharmacol. 2014;78:789-99.
10. Hajivandi A, Amiri M. World Kidney Day 2014: kidney disease and elderly. J Parathyr Dis. 2014;2:3-4.
11. Ardalan MR, Nasri H. Acute kidney injury; the focus of world kidney day in 2013. J Nephropharmacol. 2013;2:15-6.
12. Gheissari A. Acute kidney injury and renal angina. J Renal Inj Prev. 2013;2:33-4.
13. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease. Clin Nephrol. 2014;81:75-85.
14. Nasri H. Acute kidney injury and beyond. J Renal Inj Prev. 2012;1:1-2.
15. Kasahara M, Nakagawa T, Yokoi H, et al. Do statins play a role in renoprotection? Clin Exp Nephrol. 2014;18:282-5.
16. Nasri H, Sahinfard N, Rafieian M, Rafieian S, Shirzad M, Rafieian-kopaei M. Effects of Allium sativum on liver enzymes and atherosclerotic risk factors. J Herb Med Pharmacol. 2013;2:23-8.
17. Hernandez GT, Nasri H. World Kidney Day 2014: increasing awareness of chronic kidney disease and aging. J Renal Inj Prev. 2014;3:3-4.
18. El-Moselhy MA, El-Sheikh AA. Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity. Biomed Pharmacother. 2014;68:101-10.
19. Rafieian-Kopaei M, Nasri H, Nematbakhsh M, et al. Erythropoietin ameliorates genetamicin-induced renal toxicity: A biochemical and histopathological study. J Nephropathol. 2012;1:109-16.
20. Baradaran A, Rafieian-Kopaei M. Histopathological study of the combination of metformin and garlic juice for the attenuation of gentamicin renal toxicity in rats. J Renal Inj Prev. 2013;2:15-21.
21. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78-84.
22. Hajian S. Renoprotective effects of green tea. J Nephropharmacol. 2013;2:21-2.
23. Mardani S, Nasri P, Tavakoli M. Contrast induced nephropathy; recent findings. J Nephropharmacol. 2013;2:27-30.
24. Rafieian-Kopaei M, Baradaran A. Combination of metformin with other antioxidants may increase its renoprotective efficacy. J Renal Inj Prev. 2013;2:35-6.
25. Gheissari A, Mehrasa P, Merrikhi A, Madihi Y. Acute kidney injury: A pediatric experience over 10 years at a tertiary care center. J Nephropathol. 2012;1:101-8.
26. Bahmani M, Rafieian M, Baradaran A, Rafieian S, Rafieian-Kopaei M. Nephrotoxicity and hepatotoxicity evaluation of Crocus sativus stigmas in neonates of nursing mice. J Nephropathol. 2014;3:81-5.
27. Rafieian-Kopaei M. Medicinal plants for renal injury prevention. J Renal Inj Prev. 2013;2:63-5.
28. Rafieian-Kopaei M. Medicinal plants and the human needs. J Herb Med Plarmacol. 2012;1:1-2.
29. Quintavalle C, Fiore D, De MF, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126:3008-16.
30. Tavafi M. Protection of renal tubules against gentamicin induced nephrotoxicity. J Renal Inj Prev. 2013;2:5-6.
31. Nasri H, Shirzad H. Toxicity and safety of medicinal plants. J Herb Med Plarmacol. 2013;2: 21-2.
32. Iseri S, Ercan F, Gedik N, Yuksel M, Alican I. Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicology. 2007;230:256-64.
33. Yao HW, Mao LG, Zhu JP. Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin Exp Pharmacol Physiol. 2006;33:793-7.
34. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22:300-5.
35. Chung YH, Lee YC, Chang CH, Lin MS, Lin JW, Lai MS. Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure. Pharmacoepidemiol Drug Saf. 2013;22:583-92.
36. Kellick KA, Bottorff M, Toth PP, The National Lipid Association’. A clinician’s guide to statin drug-drug interactions. J Clin Lipidol. 2014;8:S30-S46.